GlassScriptPhysician profile
Ronald A Berna
NPI 1952345845
$2,704.87
in general payments reported to CMS, 2019-2025
31 companies · $843 in 2025
The $843 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $393 · 2020: $132 · 2022: $99.65 · 2023: $412 · 2024: $826 · 2025: $843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,080.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $394.76 | 2024-2025 | Tremfya |
| Janssen Biotech, INC. | $303.37 | 2024-2025 | Tremfya |
| Abbvie INC. | $235.81 | 2022-2025 | |
| Novo Nordisk INC | $199.92 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $180.29 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Otsuka America Pharmaceutical, INC. | $179.08 | 2023-2024 | Rexulti |
| Exact Sciences Corporation | $172.34 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $154.59 | 2019-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $121.94 | 2019-2024 | Veozah |
| Sun Pharmaceutical Industries INC. | $102.35 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.36 | 2019-2025 | Xifaxan |
| Pfizer INC. | $86.33 | 2019-2024 | |
| Glaxosmithkline, LLC. | $58.63 | 2019-2023 | Shingrix |
| Janssen Pharmaceuticals, INC | $53.06 | 2019 | |
| Merck Sharp & Dohme LLC | $49.02 | 2019-2025 | Gardasil 9, Capvaxive |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $46.69 | 2023-2024 | Rexulti |
| Amarin Pharma, INC. | $41.03 | 2019 | |
| Allergan, INC. | $26.43 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $25.10 | 2019 | |
| Abbott Laboratories | $23.65 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.55 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.69 | 2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $15.61 | 2023 | Eliquis |
| Idorsia Pharmaceuticals US INC | $14.57 | 2023 | Quviviq |
| Sumitomo Pharma America, INC. | $14.52 | 2025 | Gemtesa |
| Philips North America LLC | $14.19 | 2019 | |
| Xeris Pharmaceuticals, INC. | $13.49 | 2024 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $13.13 | 2019 | |
| Bausch Health US, LLC | $13.08 | 2020 | |
| Genentech USA, INC. | $12.90 | 2019 | |
| Neotract INC. | $11.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Berna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.